Part A: Number of Participants With Adverse Events of Special Interest (AESI) Through Day 29;Part A: Number of Participants With All Adverse Events (AEs) and Serious Adverse Events (SAEs) Through Day 29;Part A: Number of Participants With Disease Progression Events (Disease-Related Events) Through Day 29;Part A: Number of Participants With Worst-case Post Baseline Abnormal Electrocardiogram (ECG) Findings Through Day 29;Part B: Mean Area Under the Curve (AUC) of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Viral Load From Day 1 to Day 8 (AUCD1-8);Part C: Mean AUC of SARS-CoV-2 Viral Load From Day 1 to Day 8 (AUCD1-8)

Part A: Number of Participants With Adverse Events of Special Interest (AESI) Through Day 29;Part A: Number of Participants With All Adverse Events (AEs) and Serious Adverse Events (SAEs) Through Day 29;Part A: Number of Participants With Disease Progression Events (Disease-Related Events) Through Day 29;Part A: Number of Participants With Worst-case Post Baseline Abnormal Electrocardiogram (ECG) Findings Through Day 29;Part B: Mean Area Under the Curve (AUC) of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Viral Load From Day 1 to Day 8 (AUCD1-8);Part C: Mean AUC of SARS-CoV-2 Viral Load From Day 1 to Day 8 (AUCD1-8)

Mean area under the curve (AUC) of SARS-CoV-2 viral load in Part B study participants;Mean area under the curve (AUC) of SARS-CoV-2 viral load in Part C study participants;Occurrence of adverse events (AEs) in Part A participants;Occurrence of adverse events of special interest (AESIs) in Part A participants;Occurrence of clinically significant abnormalities on 12-lead electrocardiogram (ECG) in Part A participants readings;Occurrence of disease progression events (not classified as AEs) in Part A participants;Occurrence of serious adverse events (SAEs) in Part A participants

Mean area under the curve (AUC) of SARS-CoV-2 viral load in Part B study participants;Mean area under the curve (AUC) of SARS-CoV-2 viral load in Part C study participants;Occurrence of adverse events (AEs) in Part A participants;Occurrence of adverse events of special interest (AESIs) in Part A participants;Occurrence of clinically significant abnormalities on 12-lead electrocardiogram (ECG) in Part A participants readings;Occurrence of disease progression events (not classified as AEs) in Part A participants;Occurrence of serious adverse events (SAEs) in Part A participants

Occurrence of adverse events (AEs);Occurrence of adverse events of special interest (AESIs);Occurrence of clinically significant abnormalities on 12-lead electrocardiogram (ECG) readings;Occurrence of disease progression events (not classified as AEs);Occurrence of serious adverse events (SAEs)

Occurrence of adverse events (AEs);Occurrence of adverse events of special interest (AESIs);Occurrence of clinically significant abnormalities on 12-lead electrocardiogram (ECG) readings;Occurrence of disease progression events (not classified as AEs);Occurrence of serious adverse events (SAEs)